WebFeb 23, 2024 · In this industry-sponsored trial, empagliflozin reduced the rate of CV events and slowed the progression of kidney disease among patients with T2DM and high CV … WebAug 27, 2024 · EMPEROR-Preserved. Empagliflozin and another SGLT2 inhibitor—dapagliflozin (Farxiga; AstraZeneca)—have previously been shown to reduce adverse clinical outcomes in patients with heart failure and reduced ejection fraction (HFrEF), in the EMPEROR-Reduced and DAPA-HF trials, respectively. No trials of any …
Empagliflozin and health-related quality of life outcomes in …
WebOct 23, 2024 · The rationale and design of EMPEROR-Reduced have been previously published. 20 In short, EMPEROR-Reduced is a double-blind, placebo-controlled, parallel-group, event-driven randomized trial that … WebMar 23, 2024 · Background: Investigators have hypothesized that sodium-glucose cotransporter 2 (SGLT2) inhibitors exert diuretic effects that contribute to their ability to reduce serious heart failure events, and this action is particularly important in patients with fluid retention. Objectives: This study sought to evaluate the effects of the SGLT2 … sushi on queensway
WikiJournalClub:Usable articles - Wiki Journal Club
WebAug 30, 2024 · Now, investigators for the manufacturer-sponsored EMPEROR-Preserved trial ( NCT03059751) have randomized 5988 patients (mean age, 71 years; 45% women; … WebAug 27, 2024 · Similar to EMPEROR-Preserved, this trial enrolled patients with near normal or normal EFs, and shows a benefit in this patient population, irrespective of diabetes status. The recent American Heart Association/American College of Cardiology/Heart Failure Society of America HF guidelines designate SGLT2 inhibitor use in patients with HF with ... Webjournal o medicine n engl j med 383;15 nejm.org October 8, 2024 1413 established in 1812 October 8, 2024 vol. 383 no. 15 ... Ejection Fraction (EMPEROR-Reduced), we eval- sushi on provencher